↓ Skip to main content

Dove Medical Press

Article Metrics

New advances in the treatment of generalized lipodystrophy: role of metreleptin

Overview of attention for article published in Therapeutics and Clinical Risk Management, September 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

policy
1 policy source
twitter
5 tweeters
googleplus
1 Google+ user
video
1 video uploader

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
48 Mendeley
Title
New advances in the treatment of generalized lipodystrophy: role of metreleptin
Published in
Therapeutics and Clinical Risk Management, September 2015
DOI 10.2147/tcrm.s66521
Pubmed ID
Authors

Gilberto Paz-Filho, Alexander Rodriguez, Claudio Mastronardi

Abstract

Recombinant methionyl human leptin or metreleptin is a synthetic leptin analog that has been trialed in patients with leptin-deficient conditions, such as leptin deficiency due to mutations in the leptin gene, hypothalamic amenorrhea, and lipodystrophy syndromes. These syndromes are characterized by partial or complete absence of adipose tissue and hormones derived from adipose tissue, most importantly leptin. Patients deficient in leptin exhibit a number of severe metabolic abnormalities such as hyperglycemia, hypertriglyceridemia, and hepatic steatosis, which can progress to diabetes mellitus, acute pancreatitis, and hepatic cirrhosis, respectively. For the management of these abnormalities, multiple therapies are usually required, and advanced stages may be progressively difficult to treat. Following many successful trials, the US Food and Drug Administration approved metreleptin for the treatment of non-HIV-related forms of generalized lipodystrophy. Leptin replacement therapy with metreleptin has, in many cases, reversed these metabolic complications, with improvements in glucose-insulin-lipid homeostasis, and regression of fatty liver disease. Besides being effective, a daily subcutaneous administration of metreleptin is generally safe, but the causal association between metreleptin and immune complications (such as lymphoma) is still unclear. Moreover, further investigation is needed to elucidate mechanisms by which metreleptin leads to the development of anti-leptin antibodies. Herein, we review clinical aspects of generalized lipodystrophy and the pharmacological profile of metreleptin. Further, we examine studies that assessed the safety and efficacy of metreleptin, and outline some clinical perspectives on the drug.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Unknown 47 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 10 21%
Researcher 10 21%
Student > Master 6 13%
Student > Postgraduate 6 13%
Student > Doctoral Student 4 8%
Other 6 13%
Unknown 6 13%
Readers by discipline Count As %
Medicine and Dentistry 11 23%
Biochemistry, Genetics and Molecular Biology 7 15%
Agricultural and Biological Sciences 4 8%
Nursing and Health Professions 3 6%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Other 12 25%
Unknown 8 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 January 2021.
All research outputs
#3,003,705
of 17,489,191 outputs
Outputs from Therapeutics and Clinical Risk Management
#132
of 1,100 outputs
Outputs of similar age
#38,978
of 206,535 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#4
of 61 outputs
Altmetric has tracked 17,489,191 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,100 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,535 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 61 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.